Takeda Pharmaceutical revenue and financials
Secondary listing. The primary listing is Takeda Pharmaceutical · TSE (JPY)
$17.81Change from previous close: −0.28%Absolute change: −$0.05
In the fiscal year ended March 2026, Takeda Pharmaceutical reported revenue of ¥4.51T (−1.66% year over year). The net loss was ¥152.39B.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −1.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3.4%
- FY to Mar 2025: 2.4%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 | FY to Mar 2020 | FY to Mar 2019 | FY to Mar 2018 | FY to Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4,505,720 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 | 3,197,812 | 3,291,188 | 2,097,224 | 1,770,531 | 1,732,051 |
| Cost of revenue | 1,571,588 | 1,580,217 | 1,426,678 | 1,244,072 | 1,106,846 | 994,308 | 1,089,764 | 651,729 | 495,921 | 558,755 |
| Gross profit | 2,934,132 | 3,001,334 | 2,837,084 | 2,783,406 | — | — | — | — | — | — |
| Selling, general and administrative | 1,084,215 | 1,104,766 | 1,053,819 | 997,309 | — | — | — | — | — | — |
| Research and development | 675,924 | 730,227 | 729,924 | 633,325 | 526,087 | 455,833 | 492,381 | 368,298 | 325,441 | 312,303 |
| Operating income | 464,451 | 342,586 | 214,075 | 490,505 | 460,844 | 509,269 | 100,408 | 237,685 | 241,789 | 155,867 |
| EBIT | 5,768 | 312,395 | 172,326 | 492,063 | — | — | — | — | — | — |
| EBITDA | 726,895 | 1,073,791 | 900,328 | 1,156,463 | — | — | — | — | — | — |
| Interest expense | 148,123 | 210,065 | 219,850 | 169,698 | 166,607 | 248,631 | 165,006 | 83,289 | 31,928 | 23,249 |
| Pre-tax income | -142,355 | 175,084 | 52,791 | 375,090 | — | — | — | — | — | — |
| Income tax | 9,770 | 66,941 | -91,406 | 58,052 | 72,405 | -9,936 | -105,044 | -7,468 | 30,497 | 27,833 |
| Net income | -152,390 | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 | 44,241 | 135,192 | 186,886 | 114,940 |
| Net income to common shareholders | -152,390 | 107,928 | 144,067 | 317,017 | — | — | — | — | — | — |
| Basic EPS | 60.88 | 68.36 | 92.09 | 204.29 | 147.14 | 240.72 | 28.41 | 140.61 | 239.35 | 147.15 |
| Diluted EPS | 59.82 | 67.23 | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | 139.82 | 237.56 | 146.26 |
| Average shares (basic) | 3,150 | 3,158 | 3,129 | 3,104 | — | — | — | — | — | — |
| Average shares (diluted) | 3,206 | 3,211 | 3,161 | 3,140 | — | — | — | — | — | — |